Phase I/II Trial of Dasatinib and Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Authors
Category Primary study
JournalJOURNAL OF THORACIC ONCOLOGY
Year 2018
This article has no abstract
Epistemonikos ID: c83de8719c6db2bc771eae366e27e0d12a05792d
First added on: Feb 09, 2025